39 results about "Factor XI" patented technology

This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX and/or XI.

This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be useful for inhibiting the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway.

The present invention provides methods and compositions for treating bleeding episodes. The methods are carried out by administering to a patient in need thereof a preparation comprising a factor XI polypeptide, in an amount effective for such treatment. The methods of the invention result in one or more of: reduced clotting time; enhancement of hemostasis; increase in clot lysis time; increase in clot strength; and/or increase in overall clot quality (OCQ) in said patient.

The invention discloses a local curved surface change factor based scattered point cloud data compaction processing method. The local curved surface change factor based scattered point cloud data compaction processing method comprises the steps of 1 reading measured point cloud data, 2 calculating a central point of a point cloud, 3 searching dynamic K neighborhood points of the central point based on cubic grids and accordingly establishing the topological relation of scattered point cloud, 4 adopting a variance component method to calculate curved surface change factors of a k neighborhood of the central point, 5 determining the compaction rate of each cubic grid in the k neighborhood of the central point and performing even compaction in within a k neighborhood range. The topological relation of the scattered point cloud is established by establishing the dynamic K neighborhood point information of the scattered point cloud. Complicated curvature calculation is replaced by the curved surface change factors. The compaction ratio is adjusted according to the curved surface change factors Xi, even compaction within the k neighborhood range is achieved, the detail characteristic of high curvature can be protected, and planar characteristic of low curvature is also protected when the compaction degree is high. Point cloud data processing and curved surface reconstruction efficiency and accuracy are improved.

Compositions comprising a factor VII or factor VII-related polypeptide and a factor XI or factor XI-related polypeptide, kits comprising the same, and methods of using such compositions (e.g., in the treatment of bleeding conditions) are provided

The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.

Described are methods for preventing and/or treating bleeding in a subject with Factor XI deficiency, such as hemophilia C, which methods comprise administering to the subject APC-resistant Factor V.

Provided are assays and kits to detect ADAMTS13 activity using peptide substrates and ADAMTS13/Factor XI complexes using ELISA. These assays and kits can be used for diagnostic applications and to evaluate treatment of thrombotic or hemostatic disorders, for example, thrombotic thrombocytopenic purpura (TTP). Also provided is a novel form of ADAMTS13 found on platelets, and anti-ADAMTS13 antibodies.

Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.

The invention discloses a target spot for treating septicemia, belonging to the technical field of treatment of septicemia. The target spot is Factor XI or Factor XII, and can block a Factor XI or Factor XII expression in a septicemia patient body so as to treat septicemia. According to the invention, an antibody-14E11for blocking the Factor XI expression is a novel medicine for treating septicemia after the APC (aspirin compound tablet), and due to the special position of Factor XI on a clotting cascade chain, the occurrence rate of side effects should be obviously lower than that of the APC.

The present invention relates to a method for measuring the activated factor VII level in a sample to be tested, including the steps of: a) mixing said test sample with a plasma free of factor VII (FVII) and free of at least another factor selected from among factor VIII (FVIII), factor IX (FIX), and factor XI (FXI), the test sample + plasma having a final FVII + FVIIa concentration of 10 pM to 80 pM; b) adding initiating components from the thrombin generation reaction; c) obtaining a thrombogram when carrying out a thrombin generation test (TGT) on the mixture from step b); d) comparing at least one of the thrombogram parameters from step c) with a homologous parameter obtained from standard thrombograms established on the basis of standard samples, the activated factor VII level of which is known and varies with each standard sample; e) deducing, from step d), an activated factor VII level measurement in the test sample.

The invention relates to the field of modeling of integrated devices, and discloses a microwave photonic device modeling method based on electromagnetic field and temperature field coupling. The method comprises the following steps: measuring a temperature distribution curve of a device during independent work and an output result ri during independent work at room temperature; Measuring device output results riT at different temperatures T; Taking an output result which works independently at room temperature as a reference to obtain the influence of the temperature on the output result of the device; Establishing an ideal mathematical model output by the device, and adjusting parameters to enable an output result of the mathematical model to be the same as an output result independentlyworking at room temperature; Extracting a temperature factor Xi in the mathematical model and the influence of the temperature on the output result of the device, and inverting a function relation Xi(T) between the temperature factor and the temperature; And substituting the temperature factor Xi and the function relationship Xi (T) into the mathematical model to complete the calculation of the model output characteristic. Aiming at the field of high-integration modeling and simulation, the influence of temperature on the modeling precision of the device can be solved, the modeling speed is high, and the precision is high.

The present invention provides methods and compositions for treating bleeding episodes. The methods are carried out by administering to a patient in need thereof a preparation comprising a factor XI polypeptide, in an amount effective for such treatment. The methods of the invention result in one or more of: reduced clotting time; enhancement of hemostasis; increase in clot lysis time; increase in clot strength; and/or increase in overall clot quality (OCQ) in said patient.

The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti- Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.